Aspects of the disclosure relate to methods for determining whether or a subject is likely to respond to certain adoptive
cell therapies (e.g.,
chimeric antigen receptor (CAR) T-
cell therapy, etc.). In some embodiments, the methods comprise the steps of identifying a subject as having a
tumor microenvironment (TME) type based upon a molecular-functional (MF)
expression signature of the subject, and determining whether or not the subject is likely to respond to a
chimeric antigen receptor (CAR) T-
cell therapy based upon the TME type. In some embodiments, the methods comprise determining the
lymphoma microenvironment (LME) type of a
lymphoma (e.g.,
Diffuse Large B cell lymphoma (DLBCL)) subject and identifying the subjects prognosis based upon the LME type determination.